CLINICAL_TRIALS
trial_result
· 2023-04-07
Clinical Trial Update: Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma [Phase 2]
Summary
Phase 2 trial evaluating pembrolizumab with reirradiation in bevacizumab-naïve and bevacizumab-resistant recurrent glioblastoma; results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2023-04-07